Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

ADA 2021 June 25 - 29

Greater proportions of subjects achieved composite endpoints with once-weekly semaglutide vs comparators in SUSTAIN trials

Peter Gaede1; Andrei-Mircea Catarig2; Kathleen Dungan3; Jens Christian Øllgaard4; Stephen C Bain5;
1 Slagelse Hospital, Slagelse, Denmark; 2 Novo Nordisk A/S, Søborg, Denmark; 3 Ohio State University, Columbus, OH, USA; 4 Novo Nordisk A/S, Ørestad, Denmark; 5 Swansea University Medical School, Swansea, UK;